TargetMol

Moclobemide

Product Code:
 
TAR-T0084
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0084-10mg10mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0084-1mL1 mL * 10 mM (in DMSO)£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0084-25mg25mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0084-50mg50mg£161.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0084-100mg100mg£209.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0084-200mg200mg£275.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0084-500mg500mg£418.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Moclobemide is a reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
CAS:
71320-77-9
Formula:
C13H17ClN2O2
Molecular Weight:
268.74
Pathway:
Neuroscience; Metabolism
Purity:
0.9995
SMILES:
Clc1ccc(cc1)C(=O)NCCN1CCOCC1
Target:
MAO; Monoamine Oxidase

References

1. Da Prada M, et al. J Pharmacol Exp Ther, 1989, 248(1), 400-414. 2. Verleye M, et al. Brain Res, 2007, 1138, 30-38. 3. Reul JM, et al. Neuroendocrinology, 1994, 60(5), 509-519. 4. Cryan JF, et al. Psychopharmacology (Berl), 2005, 182(3), 335-344. 5. Girard P, et al. Can J Physiol Pharmacol, 2007, 85(5), 556-561.